News summary

Sarcopenia and Treatment Outcomes in Hepatocellular Carcinoma: Mechanistic Crosstalk, Risk Stratification, and Prospects for Intervention

Source: Frontiers - Health • Published: 13 Nov 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

Review finds sarcopenia associates with poorer outcomes after multiple HCC therapies.

Sarcopenia and Treatment Outcomes in Hepatocellular Carcinoma: Mechanistic Crosstalk, Risk Stratification, and Prospects for Intervention
Key Takeaways
  • Sarcopenia is linked to higher postoperative complication rates.
  • Sarcopenia was associated with worse survival after locoregional therapy.
  • Causality is unproven and HCC-specific prospective studies are lacking.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.